Douglas Emmett, Inc. (DEI) Reaches $40.76 52-Week High; Last Week Impax Laboratories (IPXL) Analysts

October 13, 2017 - By Vivian Park

Among 20 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 5 have Buy rating, 2 Sell and 13 Hold. Therefore 25% are positive. Impax Laboratories Inc. had 40 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Impax Laboratories Inc (NASDAQ:IPXL) earned “Buy” rating by Deutsche Bank on Monday, July 17. Cowen & Co maintained the shares of IPXL in report on Wednesday, August 9 with “Hold” rating. The firm has “Positive” rating given on Tuesday, July 21 by Susquehanna. The stock of Impax Laboratories Inc (NASDAQ:IPXL) has “Hold” rating given on Wednesday, September 13 by Canaccord Genuity. RBC Capital Markets maintained the stock with “Hold” rating in Thursday, August 10 report. Piper Jaffray maintained the shares of IPXL in report on Wednesday, August 9 with “Hold” rating. RBC Capital Markets maintained Impax Laboratories Inc (NASDAQ:IPXL) rating on Monday, June 12. RBC Capital Markets has “Hold” rating and $1500 target. Goldman Sachs initiated it with “Sell” rating and $33 target in Monday, June 6 report. The stock has “Overweight” rating by Cantor Fitzgerald on Monday, September 11. The stock of Impax Laboratories Inc (NASDAQ:IPXL) earned “Neutral” rating by Goldman Sachs on Tuesday, September 27. See Impax Laboratories Inc (NASDAQ:IPXL) latest ratings:

29/09/2017 Broker: BMO Capital Markets Rating: Hold New Target: $18.0 Maintain
28/09/2017 Broker: Goldman Sachs Rating: Neutral New Target: $20 Initiates Coverage On
15/09/2017 Broker: Piper Jaffray Rating: Hold New Target: $17.0 Maintain
14/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $17.0 Maintain
13/09/2017 Broker: Canaccord Genuity Rating: Hold New Target: $19.0 Maintain
11/09/2017 Broker: Cantor Fitzgerald Rating: Overweight Old Target: $20 New Target: $25 Maintain
31/08/2017 Broker: Raymond James Rating: Hold
10/08/2017 Broker: RBC Capital Markets Rating: Hold New Target: $17.0000 Maintain
09/08/2017 Broker: Piper Jaffray Rating: Hold New Target: $17.0000 Maintain
09/08/2017 Broker: Cowen & Co Rating: Hold New Target: $20.0000 Maintain

The stock of Douglas Emmett, Inc. (NYSE:DEI) hit a new 52-week high and has $44.43 target or 9.00% above today’s $40.76 share price. The 5 months bullish chart indicates low risk for the $6.64B company. The 1-year high was reported on Oct, 13 by Barchart.com. If the $44.43 price target is reached, the company will be worth $597.60 million more. About 288,931 shares traded. Douglas Emmett, Inc. (NYSE:DEI) has risen 18.46% since October 13, 2016 and is uptrending. It has outperformed by 1.76% the S&P500.

Since May 12, 2017, it had 0 insider purchases, and 3 selling transactions for $43,046 activity. $11,977 worth of Impax Laboratories Inc (NASDAQ:IPXL) was sold by NESTOR MICHAEL on Friday, May 12.

Investors sentiment decreased to 0.9 in Q2 2017. Its down 0.40, from 1.3 in 2017Q1. It turned negative, as 28 investors sold Impax Laboratories Inc shares while 53 reduced holdings. 24 funds opened positions while 49 raised stakes. 62.83 million shares or 2.46% more from 61.32 million shares in 2017Q1 were reported. Great West Life Assurance Can reported 106,856 shares or 0% of all its holdings. Samlyn Cap accumulated 0.22% or 554,400 shares. Alps Incorporated invested in 66,525 shares. 61,731 are held by Wells Fargo Mn. Icon Advisers Inc reported 24,800 shares. Brandywine Inv Ltd Com holds 0.01% or 105,336 shares in its portfolio. Creative Planning holds 0% or 3,054 shares in its portfolio. Fmr Limited Company accumulated 0% or 396,100 shares. Prudential Financial Inc stated it has 0% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL). Ls Advsrs Llc reported 0% in Impax Laboratories Inc (NASDAQ:IPXL). 14,548 were reported by State Of Alaska Department Of Revenue. Sector Gamma As holds 589,311 shares. Balyasny Asset Mgmt Limited Liability Company reported 1.05M shares or 0.07% of all its holdings. Sivik Glob Lc holds 1.47% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL) for 250,000 shares. D E Shaw Inc has 398,490 shares for 0.01% of their portfolio.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The company has market cap of $1.55 billion. The Firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products , in addition to the development and marketing of branded products. It currently has negative earnings. The Company’s divisions include Impax Generics and Impax Specialty Pharma.

About 548,405 shares traded. Impax Laboratories Inc (NASDAQ:IPXL) has declined 49.01% since October 13, 2016 and is downtrending. It has underperformed by 65.71% the S&P500.

Analysts await Douglas Emmett, Inc. (NYSE:DEI) to report earnings on November, 7. They expect $0.48 earnings per share, up 2.13% or $0.01 from last year’s $0.47 per share. DEI’s profit will be $78.19M for 21.23 P/E if the $0.48 EPS becomes a reality. After $0.47 actual earnings per share reported by Douglas Emmett, Inc. for the previous quarter, Wall Street now forecasts 2.13% EPS growth.

Among 15 analysts covering Douglas Emmett (NYSE:DEI), 5 have Buy rating, 2 Sell and 8 Hold. Therefore 33% are positive. Douglas Emmett has $4200 highest and $7 lowest target. $36.33’s average target is -10.87% below currents $40.76 stock price. Douglas Emmett had 42 analyst reports since August 6, 2015 according to SRatingsIntel. On Friday, May 6 the stock rating was maintained by Stifel Nicolaus with “Sell”. On Monday, July 3 the stock rating was maintained by BMO Capital Markets with “Hold”. The rating was initiated by BMO Capital Markets with “Market Perform” on Thursday, September 10. The stock of Douglas Emmett, Inc. (NYSE:DEI) has “Hold” rating given on Monday, August 31 by Zacks. The rating was upgraded by Zacks to “Buy” on Monday, September 21. The firm has “Neutral” rating by Mizuho given on Thursday, August 4. Stifel Nicolaus maintained the shares of DEI in report on Friday, July 14 with “Hold” rating. Stifel Nicolaus upgraded Douglas Emmett, Inc. (NYSE:DEI) rating on Wednesday, August 2. Stifel Nicolaus has “Buy” rating and $4200 target. BMO Capital Markets maintained the stock with “Hold” rating in Friday, October 6 report. The stock of Douglas Emmett, Inc. (NYSE:DEI) earned “Underweight” rating by Barclays Capital on Monday, August 29.

Investors sentiment increased to 1.91 in Q2 2017. Its up 0.64, from 1.27 in 2017Q1. It improved, as 10 investors sold Douglas Emmett, Inc. shares while 54 reduced holdings. 27 funds opened positions while 95 raised stakes. 153.81 million shares or 5.31% more from 146.06 million shares in 2017Q1 were reported. Bancorporation Of Montreal Can reported 345,147 shares stake. Principal Fincl Gru Inc holds 0.02% or 628,314 shares. Geode Lc holds 0.02% or 1.37 million shares in its portfolio. 96,870 were reported by Nomura Asset. Retirement Of Alabama invested 0.04% of its portfolio in Douglas Emmett, Inc. (NYSE:DEI). Thrivent For Lutherans reported 217,707 shares. Bnp Paribas Arbitrage has 103,558 shares for 0.01% of their portfolio. Honeywell Intll invested in 0.02% or 13,675 shares. Texas Permanent School Fund accumulated 0.05% or 107,220 shares. Wolverine Asset Mngmt Ltd Liability Corporation invested 0% in Douglas Emmett, Inc. (NYSE:DEI). Northwestern Mutual Wealth accumulated 24 shares or 0% of the stock. Gsa Capital Ptnrs Limited Liability Partnership holds 0.02% in Douglas Emmett, Inc. (NYSE:DEI) or 8,300 shares. Riverhead Capital Ltd Co reported 0.01% in Douglas Emmett, Inc. (NYSE:DEI). Kempen Capital Management Nv owns 0.17% invested in Douglas Emmett, Inc. (NYSE:DEI) for 46,203 shares. 481,205 are held by Barr E S Communications.

Since May 18, 2017, it had 0 insider purchases, and 2 insider sales for $7.69 million activity. The insider Emmett Dan A sold 100,000 shares worth $3.90 million.

Douglas Emmett, Inc. is a self-administered and self-managed real estate investment trust . The company has market cap of $6.64 billion. The Firm is owner and operator of office and multifamily properties located in submarkets in Los Angeles and Honolulu. It has a 69.56 P/E ratio. The Firm operates through two divisions: the acquisition, development, ownership and management of office real estate (Office Segment), and the acquisition, development, ownership and management of multifamily real estate (Multifamily Segment).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com